Skip to main content

Table 3 Univariate and multivariate logistic regression analysis of overall survival

From: Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study

Parameter

Univariate

Multivariate

HR (95% CI)

P value

HR (95% CI)

P value

Sex (men vs. women)

1.02 (0.61–1.72)

0.912

  

Age (< 70 vs. ≥ 70 years)

1.19 (0.72–1.95)

0.488

  

Preoperative CA19-9 (< 338.45 vs. ≥ 338.45)

1.04 (0.60–1.80)

0.871

  

Tissue size (3, 4 vs. 1, 2)

1.12 (0.56–2.22)

0.754

  

ly (positive vs. negative)

3.50 (1.09–11.2)

0.035a

2.27 (0.56–9.09)

0.246

v (positive vs. negative)

1.36 (0.96–1.93)

0.082

  

Pathological T factor (≥ 3 vs. < 3)

1.09 (0.15–7.95)

0.928

  

Lymph node metastasis (positive vs. negative)

2.69 (1.07–6.75)

0.034a

2.03 (0.74–5.52)

0.164

Residual tumor (≥ 1 vs. 0)

1.94 (0.94–4.01)

0.073

  

Time to start AC (≥ 42 vs. < 42 days)

1.21 (0.65–2.22)

0.527

  

TDI (< 62.5% vs. ≥ 62.562.5)

3.10 (1.86–5.15)

 < 0.001a

3.38 (2.01–5.70)

 < 0.001a

  1. HR Hazard ratio, ly Lymphatic permeation, v Blood vessel invasion, AC Adjuvant chemotherapy, TDI Total dose intensity
  2. aStatistically significant